Pfizer Inc.’s decision late last week to shelve the twice-daily form of its oral GLP-1 danuglipron means the US giant has slipped down the rankings of companies trying to bring oral forms of incretin drugs – the wildly successful therapies for diabetes and obesity – to market.
Key Takeaways
- Several groups, including recent entrants Roche and AstraZeneca, are pursuing oral incretins for diabetes and obesity
And this week a new player entered this space: Roche Holding AG obtained a Phase I-stage oral incretin, CT-996,...
